Spinal tissue degeneration

Spinal tissue degeneration, primarily manifesting as intervertebral disc degeneration (IVDD), is a complex pathological process involving the progressive loss of structural integrity in the spinal column (StatPearls, 2023). It is characterized by a shift in the homeostatic balance of the extracellular matrix (ECM), where catabolic activities of enzymes like matrix metalloproteinases (MMPs) and ADAMTS exceed the anabolic production of collagen and proteoglycans (PubMed, PMC10143545). This process is heavily mediated by pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1 beta (IL-1β), which serve as the primary therapeutic targets for emerging biological treatments (NIH, 2022). While "Spinal tissue degeneration" describes a clinical condition rather than a single protein or receptor, drug development in this field focuses on inhibiting these inflammatory mediators or utilizing growth factors like BMP-7 to stimulate tissue repair (Journal of Orthopaedic Research, 2021). Effective management remains a challenge due to the avascular nature of the disc, which limits the delivery and efficacy of systemic pharmacological agents (Nature Reviews Rheumatology, 2020).

Other names

Intervertebral disc degenerationDegenerative disc diseaseSpondylosisSpinal osteoarthrosisDegenerative spondylolisthesis

Therapeutic strategies involve the inhibition of pro-inflammatory cytokines (TNF-alpha, IL-1), neutralization of Nerve Growth Factor (NGF), or the use of anabolic growth factors to restore extracellular matrix homeostasis.